FDA Wants More REMS Authority To Speed Negotiations With Sponsors
Executive Summary
FDA would like Congress to provide the agency with a larger role in writing Risk Evaluation and Mitigation Strategies, Principal Deputy Commissioner Joshua Sharfstein indicated during a House Energy and Commerce Health Subcommittee hearing on March 10
You may also be interested in...
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.
Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.